Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Potassium channel tetramerization domain-containing protein 6 (KCTD6) is a member of the KCTD protein family, named for their N-terminal BTB/POZ domain, which bears sequence similarity to potassium channel tetramerization domains. KCTD6 primarily serves as a substrate-specific adaptor for cullin-3 E3 ubiquitin ligase complexes, mediating the selective ubiquitination and proteasomal degradation of proteins such as muscle ankyrin-1 isoform 5 and HDAC1. This regulation influences processes such as muscle protein turnover and Hedgehog pathway signaling. KCTD6 forms parallel homotetrameric complexes via its BTB/POZ domain and is important for maintenance of muscle structure and potentially other cellular processes. Dysfunction or altered expression of KCTD6 has been linked to muscle disorders and may have relevance in developmental and oncogenic contexts.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Potassium channel tetramerization domain-containing protein 6 (KCTD6).